CEA carcinoembryonic 24h urine
Selected indexed studies
- Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer. (Sci Rep, 2021) [PMID:34907230]
- Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. (Cancer Res, 1995) [PMID:7493373]
- A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. (Clin Cancer Res, 2000) [PMID:11051230]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer. (2021) pubmed
- Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. (1995) pubmed
- A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. (2000) pubmed